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Abstract 
We formulate and analyze a mathematical model describing immune response to avascular 
tumor under the influence of immunotherapy and chemotherapy and their combinations as 
well as vaccine treatments. The effect of vaccine therapy is considered as a parametric 
perturbation of the model. In the case of a weak immune response, neither immunotherapy 
nor chemotherapy is found to cause tumor regression to a small size, which would be below 
the clinically detectable threshold. Numerical simulations show that the efficiency of 
vaccine therapy depends on both the tumor size and the condition of immune system as 
well as on the response of the organism to vaccination. In particular, we found that vaccine 
therapy becomes more effective when used without time delay from a prescribed date of 
vaccination after surgery and is ineffective without preliminary treatment. For a strong 
immune response, our model predicts the tumor remission under vaccine therapy. Our study 
of successive chemo/immuno, immuno/chemo and concurrent chemoimmunotherapy shows 
that the chemo/immuno sequence is more effective while concurrent chemoimmunotherapy 
is more sparing.  
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1. Introduction 
Some modern trends in treatment of cancer are based on the ability of certain forms 
of tumors to stimulate immune response. The fact that the immune system plays an 
important role in fighting cancer has been verified both in laboratorial and clinical 
experiments [15,34]. An inclusion of immune component in mathematical models of 
tumor growth has been shown to reflect clinically observed phenomena such as 
uncontrolled growth of tumor, tumor dormancy and oscillations in tumor size 
[1,8,10,11,16,24,25,44,47]. A similar tumor behavior was also predicted in our recent 
ODE model [22] with the interleukine-2 (IL-2) taken into account. 
The goal of immunotherapy is to enhance the anti-tumor resistance of an organism 
and improve the immune system condition. There are known three main categories of 
immunotherapy: immune response modifiers (cytokines), monoclonal antibodies and 
vaccines [40]. Such immune modifiers as IL-2, interferon-α (IFN−α) as well as tumor 
necrosis factor- α (TNF−α) are already widely used in cancer immunotherapy 
[4,5,19,20,41,48]. An important problem is to choose the correct schedule for using 
chemotherapy in combination with IL-2 and IFN−α therapy. For example, a series of 
sequential phase II trials based on integrating of IL-2 and IFN−α with the CVD 
(cisplatin, vinblastine, and dacarbazine) regimen shows that chemotherapy followed 
immediately by immunotherapy is more effective for treatment of human metastatic 
melanoma than their reverse sequence [4,5]. It was also observed that concurrent 
chemoimmunotherapy is almost as effective as chemo/immune sequence when 
immunotherapy is administered right after the CVD. At the same time, the concurrent 
chemoimmunotherapy is found to be less toxic than the sequential regimens [4]. 
Monoclonal antibodies (MA) are used in both diagnostics and therapy of cancer. This 
follows from ability of MA to recognize tumor antigens on a surface of tumor cells. As 
a result, MA can deliver both anti-tumor drugs and radioactive isotopes exactly to the 
malignant cells [27,37]. In spite of the fact that cancer vaccines are still under 
experimental investigations, the existent clinical trials clearly show that they can 
improve immune response to certain forms of cancer [40,50]. Most of cancer vaccines 
consist of living tumor cells and their lysis products while some of them contain tumor-
derived proteins, peptides and gangliosides [42]. For instance, an experimental vaccine 
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for malignant melanoma consists of four melanoma peptides restricted by HLA-A1, A2, 
A3 and HLA-DR and includes IL-2 and granulocyte macrophage colony stimulating 
factor (GM-CSF) as adjuvants. It was found that this vaccination is able to stimulate 
tumor regression in some cases [45,46]. The observed toxicity of this vaccination is 
connected with low doses of IL-2. These findings stimulated our interest to consider 
within our model the effects of combination immune and chemotherapy treatments as 
well as vaccine therapy. 
One of the first attempts to consider effects of immunotherapy within an 
appropriate ODE model was made by Kirschner and Panetta in [24]. They study 
immunotherapy based on the use of IL-2 together with adoptive cellular immunotherapy 
(ACI) by introducing in dynamical equations terms describing external inflow of both 
IL-2 and cultured immune cells. More recently, de Pillis and Radunskaya have proposed 
the kinetic model of anti-tumor immune response where individual equations were 
suggested for the description of mechanisms of natural immunological defense 
presented by NK-cells and specific immune response presented by CD8+ T cells 
[10,11]. Notice that unlike [24] they do not consider a natural dynamics of IL-2. In the 
framework of this model the effects of chemotherapy, immunotherapy, their combined 
influence, as well as the vaccine therapy were considered [11].  
It is interesting to mention a recent paper by Arciero et al. [2] where a novel 
treatment strategy known as small interfering RNA (siRNA) therapy was considered in 
the framework of the model proposed in [24]. This treatment suppresses TGF-β 
production by targeting the mRNA codes for TGF-β, thereby reducing the presence and 
effect of TGF-β in tumor cells. The model predicts conditions under which siRNA 
treatment can be successful in transformation of TGF-β producing tumors to either non-
producing or producing a small value of TGF-β tumors, that is to a non-immune 
evading state. 
In recent years, the importance of spatial aspects of tumor-immune dynamics was 
demonstrated [30-32,35,36]. For example, in [31,32] the tumor cell distributions that are 
quasi-stationary in time and heterogeneous in space were studied within the PDE model 
by Matzavinos and Chaplain based on the ODE model by Kuznetsov [25]. It was found 
that depending on model parameters this reaction-diffusion-chemotaxis system is able to 
simulate the well-documented phenomenon of cancer dormancy, as well as tumor 
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invasion which is presented in the form of a standard traveling wave. The interesting 
PDE model of non-specific immune response was developed by Owen and Sherrat in 
[35,36]. The important conclusion of this model is that macrophages are unable to 
prevent tumor growth. Nevertheless, significant effects on the form of the tumor were 
predicted, including the formation of spatial patterns. The model demonstrates the 
existence of traveling wave solutions connecting the normal tissue and tumor steady 
states corresponding to a growing tumor. When macrophage chemotaxis is included, 
these patterns can in some cases bifurcate to give irregular spatiotemporal oscillations.  
Finally, let us mention the hybrid cellular automata–PDE modeling approach which 
combines continuous PDEs for chemical quantities and a discrete cell-based description 
for biological cell species with phenomenologically sourced probabilities for cell 
dynamics [30]. This approach allows one to consider both temporal and two-
dimensional spatial evolution of the system. Numerical simulations include spherical 
tumor growth, stable and unstable oscillatory tumor growth, satellitosis and tumor 
infiltration by immune cells.  
Our model of immune response to early (avascular) tumor growth is based on the 
mechanism of intercellular cytokine mediated interaction in cellular immune response 
proposed by Wagner et al. [49] which was modified by taking into account co-
stimulatory factors (see, e.g., [28,39]). Generally, it consists of seven ordinary 
differential equations. To simplify analysis, we reduced the model to three equations 
incorporating the most important modern concepts of tumor-immune dynamics 
including the influence of IL-2 dynamics (see [22] for details). Notice also that we do 
not consider the spatial migration of cell populations that is of most importance for 
modeling of angiogenesis (vascular growth), invasion and metastasis (see, e.g., [7]).  
In this paper, we extend our model [22] to describe chemo- and immunotherapy 
effects. The outline of the paper is as follows. First of all, a mathematical model of 
tumor-immune dynamics under the influence of both immunotherapy with IL-2 and 
IFN−α and chemotherapy is formulated in section 2. In section 3 we perform a steady 
state analysis of the model. The results of numerical studies are presented in section 4 
for four different cases: chemotherapy alone, IL-2 alone, IL-2 plus IFN−α, and a 
combination of chemotherapy and immunotherapy (IL-2 therapy). The effects of 
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vaccine therapy are considered in the absence of chemotherapy and immunotherapy. 
Section 5 is devoted to conclusions and discussion. 
2. Mathematical model 
The system (1)—(5) describes the most important components of tumor-immune 
dynamics in the presence of treatment components. Namely, we consider five 
populations: tumor cells (T), CTL (L), IL-2 (I2), chemotherapeutic drug (C), and IFN−α 
(I). 
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The tumor growth is described by the Gompertzian law (the first term in (1)). The 
destruction of tumor cells by CTL is presented by the second term in (1). It is supposed 
that the destruction rate is proportional to the number of tumor cells and CTL 
populations. In (2) d characterizes the steady inflow of CTL into the tumor site. Second 
and third terms in (2) describe CTL proliferation in response to the IL-2 action and CTL 
death rate, correspondingly. In (3)—(5) Vi (i=I2, C, I) describes the external influxes of 
IL-2, chemotherapeutic drug and IFN−α, respectively. Since therapy is assigned to a 
certain schedule, these influxes are taken to be time-dependent. IL-2 production in (3) is 
described by hyperbola (the second term), which allows us to take into account a 
limitation in the stimulation of the immune system by the growing tumor. At small T the 
growth rate is nearly linear in tumor size while for big tumor (T >> l) it tends to a 
maximum constant value g. The parameter l influences the IL-2 production rate. The 
smaller is the value of l, the quicker the IL-2 production rate achieves its maximum 
value g. Notice that g characterizes the degree of expression of the antigen plus major 
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histocompatibility complexes class II (AG-MHC-II) on the APC surfaces, i.e. the 
antigen presentation. The probability of activation (provoking the IL-2 production) of 
helper T cell precursor by the APC increases with the antigen presentation. Since IL-2 is 
a short-distance cytokine, it is suggested that target cells (cytotoxic T lymphocytes) 
effectively consume IL-2. The consumption rate is presented by the third term in (3). It 
was found that inhibition of IL-2 results from an accumulation of immune-suppressing 
substances, prostaglandins. Their number is proportional to the concentration of tumor 
cells. Prostaglandins suppress the production of IL-2 and can directly destroy its 
molecules [38]. In (3) the IL-2 destruction rate is described by the fourth term. 
The interaction of chemotherapeutic drug with sensitive cells can be described by 
using of either the Michaelis-Menten kinetics [23] or the exponentially saturating 
kinetics [11]. Similarly to [11], we use in Eqs. (1) and (2) a saturation term 
jeIM Cj ))(( −−12  with j = T, L to describe cell death caused by chemotherapeutic drug. 
At low concentrations the death rate is nearly linear in drug while at higher 
concentrations the death rate turns out to be C-independent. As was noted in [11] this 
behavior shows a good correlation with existing dose-response curves (see, e.g., [18]). 
We assume that Mj depends on the IL-2 concentration in the following way: 
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−= . Thus, Mj increases with the concentration of IL-2, 
however, it never exceeds a doubled value of chemojM  (cell killing by chemotherapy). 
This is based on the fact that IL-2 can induce the secondary cytokines such as TNF-α , 
which could enhance the anti-tumor effect of cytotoxic chemical agents (see, e.g., [5]). 
We also suppose that the model parameter c in (1) depends on the IFN−α concentration 
as )()( CTL 02 I
I
ecIc
−
−= , where CTLc  is a rate of tumor cells inactivation by CTL. This 
agrees with the fact that IFN−α enhances immune-mediated anti-tumor responses by 
increasing expression of MHC molecules on tumor cells, thus enhancing their 
recognition by CTL [48]. Notice that only therapeutic IFN−α dynamics is considered 
within our model.  
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2.1. Parameter set 
As is shown in our previous work [22], possible scenarios of tumor-immune 
dynamics are very sensitive to the choice of the parameters in equations (1)—(5). In fact 
the parameter sets vary not only for specific cancer types but also from one individual to 
another. Our model is based on using of some generalized (most typical) parameters. In 
order to reflect the individual clinical outcomes we conditionally divide patients in three 
groups (see Tables 1 and 2). We assume that tumor has the same histological structure 
(for instance, melanoma) with equal doubling time and carrying capacity (actually, 
these characteristics may vary between tumor specimens). Additionally, the lifetime of 
CTL is chosen to be the same. On the other hand, the tumor antigen expression (cCTL), 
the strength of the immune response (e, g, j and k), and the reaction to vaccination are 
taken to be specific for each group. Some values of model parameters were estimated by 
using the available experimental data. In particular, the human melanoma growth 
parameters a and b were obtained from the experimental data found in Hu’s results on 
mice trials where human melanoma was tested in a severe combined immunodeficient 
mice [21]. Using the least-squares method, we fitted the experimental curve produced 
by the data of a control group to Gompertzian curve. The death rate of CTL was 
estimated using the relation f = 1/τ where τ is their known average lifetime. The rate of 
steady inflow of CTL was calculated from the relation d = fLfree where Lfree (the number 
of CTL capable to recognize melanoma specific antigen in the organism without tumor) 
was estimated to be about 2.25×107 cells using the data for the full number of CD8+ T 
cells in blood and a percent value of T cells specific for melanoma antigen [17]. The 
parameters characterizing the cell death caused by chemotherapeutic influence chemoTM  
and chemoLM  are taken from de Pillis’s model [11]. The elimination rates for 
chemotherapeutic drug (dacarbazine) and IFN−α were estimated by using their known 
half-life times and the relations: p = ln2/tC1/2 and q = ln2/tI1/2 (see, for example, [29,43]). 
For the rest of parameters we chose values most appropriate to our model. Current 
medical literature and sensitivity analysis (see [22]) allow us to conclude that the 
corresponding interactions are of importance in the description of immune response. 
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3 Non-dimensionalization, steady state analysis 
3.1. Scaling 
For convenience let us introduce dimensionless variables and parameters as 
follows: ,/ 0TTT =′  L′ = L/L0, 2I ′  = I2/I20, I′ = I/I0 and t′ = t/τ, where τ = 
1−f  (days). 
The values of T0, L0, I20 and I0 are given in accordance with [24] and presented in Table 
1. Notice that the variable for chemotherapeutic drug, C, is given in relative units. The 
choice of the time-scale factor τ is based on the fact that the mean lifetime of CTL is 
about three days and a similar time is needed for the proliferation of CTL and IL-2 
production [6,9]. 
Dropping primes for notational clarity, equations (1)—(5) take the following form 
in normalized units: 
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where h1 = a/f, h2 = bT0/f, h3 = cCTLL0/f, m1 = chemoTM /f, h4 = d/fL0, h5 = eI20/f, 
m2 = 
chemo
LM /f, m3(t) = 2IV (t)/fI20, h6 = g/fI20, h7 = jL0/f, h8 = kT0/f, h9= l/T0, 
m4(t) = VC(t)/f, m5 = p/f, m6(t) = VI(t)/fI0, and m7 = q/f. 
3.2. Steady state analysis 
To perform a steady state analysis we study the system 
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which follows from (6)—(10) at Vi(t) = 0 (i = I2, C, I) and C(0) = I(0) = 0. 
A possible way to perform the steady state analysis is to use isoclines. Let us 
consider the phase plane TL, which shows the interactions between two main cell 
populations: tumor cells and CTL. In this case, the equations for horizontal and vertical 
isoclines are written as  
 0))()(( 658794 =+++− TLhhThLhhTLh , (14) 
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The fixed points are situated at the intersections of isoclines (14) and (15). Our 
analysis shows that at any choice of parameters the system (11)—(13) has the unstable 
point (0, h4, 0), which lies at the intersection of isoclines (14) and T = 0. This means that 
the regime of full tumor regression is not allowed. 
We consider g (characterizing the antigen presentation) as a varying parameter. A 
bifurcation diagram for the dimensionless parameter h6 is presented in Figure 1 where 
the function h6(T) is obtained by substitution of L from (15) into (14). As is seen, there 
are two bifurcation points. Therefore one can distinguish three main dynamical regimes. 
The region I (h6 < h6min) characterizes the weak immune response. The system (11)—
(13) has two fixed points: a saddle point (0, h4, 0) and an improper node (T3, L3, I23). 
This means that under a deficiency in the production of IL-2, the population of tumor 
cells is able to escape from the immune response. The tumor grows and the immune 
system becomes suppressed. In the region II (h6min < h6 < h6max), which we associate 
with the strong immune response, there appear two additional fixed points: a stable 
spiral (T1, L1, I21) and a saddle (T2, L2, I22). Therefore different regimes can exist 
depending on the initial conditions. First, when initial CTL population size is 
sufficiently large to reduce a tumor population, the regression of tumor up to a small 
fixed size where the dynamical equilibrium between tumor and immune system is 
reached. In this case, the tumor manifests itself via the excited immune system. Second 
regime appears when initial number of CTL is not large enough to drive the system at 
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the dynamical equilibrium point (T1, L1, I21), which is a stable spiral. Thus, the tumor 
grows to a highest possible size, which is defined for the tumor population being in 
conditions of restricted feeding. The dynamical equilibrium between the tumor and the 
immune system is reached at the fixed point (T3, L3, I23) that is an improper node. 
Finally, in the region III (h6 > h6max) the fixed points (T2, L2, I22) and (T3, L3, I23) 
disappear. As a result, there are two fixed points: a saddle point (0, h4, 0) and a stable 
spiral (T1, L1, I21). In this case, a decrease in tumor size is found when the equilibrium 
between the tumor and the immune system is established. The region III is associated 
with the dormant tumor when the immune system is able to handle the tumor size.  
4 Numerical experiments 
In this section we study the effects of chemotherapy alone, IL-2 alone, IL-2 plus 
IFN-α therapy, regimens of sequential chemoimmunotherapy as well as vaccine therapy 
for three groups of patients. Two of them (P1 and P2) generate weak immune responses 
to the tumor while the third one (P3) generates a strong immune response. The group P2 
is characterized by a lower antigen expression in comparison with P1 and, 
correspondingly, exhibits a weaker immune response (see Tables 1 and 2). At the stage 
II of malignant melanoma both chemotherapy and immunotherapy are usually 
administered after surgical treatment. Therefore, the initial tumor size is assumed to take 
a hypothetical value of T(0) ~ 8×106 cells. When we study the effects of treatment 
administered without preliminary surgery, the initial tumor size is assumed to take a 
hypothetical value of 3×107 cells. In subsections 4.1—4.6 we will consider the first 
group of patients (P1).  
4.1. Chemotherapy 
Let us test a treatment approach which employs nine pulsed doses of chemotherapy, 
each dose represented by setting VC(t) = 1 in (4) for a day, and given once every 5 days 
(Figure 2(d)). As is seen from Figure 2(a), a regression is not observed and the tumor 
population grows. The number of tumor cells oscillates in time as a result of pulsed 
character of dosing. Tumor growth rate is found to decrease in comparison with the case 
without treatment. This is completely due to chemotherapeutic influence because the 
CTL dynamics is slightly affected by chemotherapy (see Figure 2(b)). A possible reason 
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is that an increase in CTL proliferation caused by increasing IL-2 concentration is 
compensated by death of CTL under the action of chemo-drug. Thus, our study shows 
that chemotherapy results in stunted tumor growth. In particular, at our choice of 
parameters the tumor achieves its dangerous size about ten days later than in the 
absence of the therapy. 
4.2. Immunotherapy 
IL-2 alone 
 
The following regimen of the IL-2 alone therapy is supposed: four pulsed doses of 
IL-2, each is equal to 10 MU/day for four days, and administered every 10 days. As is 
seen from Figure 2(a), there is a tumor remission with the duration of about 40 days. At 
the same time full tumor regression is not observed. Indeed, as IL-2 concentration 
grows, the CTL population is also increased approximately by a factor of 7 in 40 days 
(see Figure 2(b)). However, approximately ten days after treatment cessation the IL-2 
concentration decreases (see Figure 2(c)). Accordingly, the CTL population also 
regresses and, as a result, the tumor growth revives. Thus, this course of treatment leads 
to a temporary remission only (for 1—1.5 months in our case). 
 
IL-2 plus IFN-α 
 
Let us consider a combined course of the immunotherapy, when IL-2 and IFN-α 
are given simultaneously. The dose administration pattern for IL-2 is considered to be 
the same as in the previous subsection. Together with IL-2 the IFN-α at the dose 
5 MU/day for four days in a 10 day cycle is administered (Figure 2(d)). As is shown in 
Figure 2(a), there is a substantial decrease in the number of the tumor cells during the 
cure. The tumor remission becomes more pronounced in comparison with the previous 
case although the regression time is almost the same. 
Thus, our study shows that immunotherapy is more effective in the remission time 
of the tumor as compared with chemotherapy. As another conclusion, the IL-2 alone 
therapy should be considered as more sparing treatment in comparison with the case of 
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IL-2+IFN-α. Indeed, in spite of better tumor remission for IL-2+IFN-α treatment the 
IL-2 alone therapy is less toxic. 
4.3. Sequential chemo/immunotherapy 
In the next three subsections, we study the effects of chemotherapy followed 
immediately by immunotherapy or vice versa, as well as the concurrent 
chemoimmunotherapy. We consider the following sequential therapy regimen: one 
pulse of chemotherapy is presented by setting in (4) VC(t) = 1 per day for four days 
(Figure 3(d)). During the next four days one pulse of IL-2 therapy is administered in 
amounts of 
2IV (t) = 10 MU/day in (3). Figure 3(a) shows the dynamics of tumor cells. 
As is seen, the chosen regimen of sequential therapy does not lead to the tumor 
regression. However, a markedly stunted tumor growth is observed (tumor cell 
population reaches the maximum value about thirty days later in this case). At the initial 
stage (t < 8 days), the tumor growth deceleration is entirely due to chemotherapeutic 
impact. Furthermore, the tumor cell population slightly decreases. This effect is caused 
by an increase of the IL-2 concentration during eight days (see Figure 3(c)), which leads 
to both a recovery of the CTL number (that has been decreased by chemotherapy) and 
its following increase (see Figure 3(b)). Later on, the tumor steadily grows and the 
suppression of the immune functions takes place. Notice, that tumor growth rate at this 
stage is smaller than for t < 8 days. Thus, although this sequential regimen does not lead 
to the tumor regression it allows one to delay the tumor growth. 
4.4. Sequential immuno/chemotherapy 
Let us consider the following sequential regimen: one pulse of the IL-2 therapy, 
which is presented by setting in (3) 
2IV (t) = 10
 MU/day for four days. For the next four 
days one pulse of chemotherapy is administered in dose VC(t) = 1 in (5) per day for four 
days (Figure 3(d)). The dynamics of tumor cells is shown in Figure 3(a). As is seen, the 
result of this sequential regimen is worse in comparison with the previous case. Indeed, 
the IL-2 dosing leads to the increase of its concentration (Figure 3(c)) and, accordingly, 
to the increase of the CTL number (Figure 3(b)). However, the CTL have not enough 
time to achieve the magnitude sufficient to slow down the tumor evolution since their 
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growth is abruptly stopped due to chemotherapy (see Figure 3(b)). Nevertheless, at the 
termination of course of treatment the CTL number again increases due to a sufficiently 
high concentration of IL-2. As a result, the tumor growth becomes slower reaching a 
dangerous size twenty days later than in the absence of therapy. 
4.5. The concurrent biochemotherapy 
The regimen of the sequential therapy is chosen to be the following: the 
chemotherapy in dose VC(t) = 1 per day and the IL-2 therapy in dose 
2IV (t) = 7 MU/day 
are given simultaneously for four days. Since the concurrent chemoimmunotherapy is 
found to be less toxic in comparison with other sequential regimens (see, e.g., [15]), the 
dose of the IL-2 is selected to be approximately 3⋅106 units less than in subsections 4.3 
and 4.4. As a result, the tumor cell dynamics becomes a little higher in comparison with 
the first sequential regimen in 4.3 during a period of time that is long enough, except for 
the initial interval of (0; 10) days (see Figure 3(a)). For this period of time, the tumor 
growth deceleration is more pronounced in comparison with the case of chemo/immuno 
sequence. Indeed, since chemotherapy and IL-2 therapy are used simultaneously, the 
tumor cells die under the action of both drug and the immune response recovered by IL-
2 therapy. As is seen from Figure 3(b), the dynamics of CTL is similar to that without 
therapy. For the first six days the IL-2 concentration is higher than in the case of 
chemo/immunotherapy (Figure 3(c)). Thus, our simulations show that the stronger 
increase of the IL-2 concentration prevents the reduction in the CTL number caused by 
the chemical impact (unlike the first sequential regimen). In turn, for the next four days 
the IL-2 concentration becomes lower as compared with the case of 
chemo/immunotherapy. Therefore, one can conclude that the concurrent 
chemoimmunotherapy is more favorable in comparison with the regimen considered in 
the subsection 4.3. 
4.6. Vaccine therapy 
Cancer vaccines are considered as one of promising methods of immunotherapy. 
Using vaccine allows sensitizing the immune system to the presence of the certain 
forms of cancer. As a consequence, the immune system will be able to find and lyse 
tumor cells more effectively. When vaccine appears in the body the anti-tumor 
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lymphocyte formation occurs. The efficacy of the vaccination depends on the following 
factors: (i) the number of tumor cells and their mitotic activity, (ii) the type of tumor, 
i.e. its histological structure, antigen structure, the number of HLA-A molecules 
expressed on the tumor cells and (iii) initial conditions of the immune system. 
In this subsection, we consider a cancer vaccine consisting of four tumor-derived 
peptides with an adjuvant (see, for example, [33] for a current list of ongoing trials). As 
long as antigen/adjuvant complexes stimulate immune response to vaccine thereby 
enhancing immune reaction to patient’s tumor cells, the effect of the vaccination can be 
taken into account through the model parameters. Therefore, in order to simulate 
vaccine therapy we change the values of four model parameters at the time of 
vaccination (in a similar manner as in [11]). The parameters that are sensitive to 
vaccination can be extracted from the experimental results obtained on mouse vaccine 
trials by Diefenbach et al [14]. Namely, we fitted the experimental curves produced by 
Diefenbach’s data to our model and found the parameters that would change to reflect 
the administration of a therapeutic vaccine. They are cCTL, the rate of inactivation of 
tumor cells by CTL; e, the rate of CTL proliferation induced by IL-2; g, the antigen 
presentation (the probability of interaction between helper T cell precursors and APC); 
and j, the rate of consumption IL-2 by CTL. Finally, to simulate vaccine therapy we 
alter the corresponding model parameters in the same direction as they change in 
Diefenbach’s murine model [14] (cf. [11]). As a result, all four parameters (cCTL, e, g, 
and j) are found to be increased.  
We present here the results for vaccine therapy alone, so that we put VC(t), 
2IV (t), 
VI(t) equal to zero as well as C = I = 0 in (1)-(5). The regimen of vaccination chosen for 
simulation of vaccine therapy is the following: the cancer vaccine administered once a 
week during 1—3, 5—7, 13, 27, 40, and 53 weeks, respectively [33]. We suppose that 
the vaccine is effective 83 days after the last injection. This value is not imperative. It 
seems plausible that this action may last even longer. We assume that at the expiration 
of this period the system parameters are restored to their initial values. As a result, 
tumor growth restarts. Therefore revaccination is required to avoid a disease recurrence.  
From the above discussion it is clear that the values of parameters cCTL, e, g, and j 
will depend on the regimen of vaccination, i.e. on time. In other words, during the 
vaccine action we increase parameters by a certain percent value (see Table 3). Under 
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these assumptions, the steady-state conditions for P1 become changed in such a way 
that the system (11)—(13) passes to the region II on the bifurcation diagram (see Fig.1 
and Figure 4). Remember that in this region treatment outcome markedly depends on 
the initial tumor size and the immune system conditions. Figure 5 shows the results for 
two courses of the vaccination: the first one was administered without delay while the 
second one was administered 10 days later, when tumor cell population has reached a 
sufficiently large value to escape the immune response (Figure 5(a), 5b, 5c).  
Let us first analyze the behavior of the system under the vaccine administered after 
surgery. For therapy without delay, the initial number of tumor cells is enough to induce 
the immune response. As is seen from Figure 5(c), the IL-2 concentration grows and, 
consequently, the CTL number is increased. The integral curves tend to the stable spiral 
point and the long tumor remission is observed (Figure 5(a)). Assumed 10-day delay is 
simulated by a time displacement t → t + 10. In this case, the tumor has time to reach a 
sufficiently large size and both the IL-2 concentration and CTL number are decreasing 
(Figure 5(b) and 5c). The integral curves tend to the improper node, which means 
progressive tumor. The simulations show that the earlier the vaccination is administered 
the more effective it is for the cancer treatment. 
Let us simulate the vaccine administered without previous surgery. Figure 6(a) 
shows that even for the therapy without delay the tumor regression does not occur and 
only some stunted tumor growth with lower saturation level is observed in comparison 
with the case without therapy. One can suppose that the saturation level without therapy 
corresponds to a dangerous tumor size in stage II of malignant process. Then the lower 
saturation level with vaccination may be considered as a steady state of a patient during 
the vaccine action (Figure 6(a)). In the case of 10-day delay, the tumor size almost 
reaches the therapeutic saturation level (Fig 6a). As is seen, the vaccine-mediated 
enhancement of the immune response prevents tumor growth to reach a dangerous size. 
Namely, after 15 days of growth the tumor curve goes slightly down and tends to the 
therapeutic saturation level. This does not mean, however, that a delay in the 
vaccination is not dangerous. In fact, as mentioned above, we do not take into account 
the angiogenesis, which begins at certain size of the tumor and provokes its further 
explosion [2,7]. In other words, the existence of the saturation level does not imply the 
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termination of the tumor growth. Figs. 6b and 6c show dynamics of CTL and IL-2, 
respectively. 
4.7. Comparison with second and third groups of patients 
Table 4 summarizes the main findings of subsections 4.1—4.6 for the first group of 
patients as well as presents the results for two other groups. Let us compare three groups 
of patients. According to Table 4, for the second group of patients the IL-2 alone and 
IL-2 plus IFN-α therapies result in slower tumor expansion as compared to 
chemotherapy. After 6 weeks of the IL-2 alone therapy the tumor volume reaches 
almost the same value as in the case of chemotherapy. Results of chemo/immuno 
regimen are found to be similar to immuno/chemo and concurrent 
chemoimmunotherapy. This markedly differs from the first group where the increase of 
tumor size for chemo/immune sequence is smaller in comparison with the reverse 
sequence. Therefore, one can conclude that the dependence on the schedule is more 
pronounced in the first group. As a possible reason, the IL-2 therapy is less effective in 
the second group. This is a result of lower tumor antigen expression when stimulation of 
CTL proliferation by IL-2 becomes insufficient for effective recognition of tumor cells. 
Although the IL-2 plus IFN-α therapy looks more favorable for P2 in comparison with 
other therapies, one has to bear in mind that the vaccine therapy is less toxic. Let us 
consider the behavior of the second group of patients in response to the vaccination 
more detail. The increase of corresponding parameters for P2 during the vaccine action 
is shown in Table 3. As is seen, the suggested values differ from these for P1. Figure 4 
shows that in this case the steady-state conditions do not change. This result looks rather 
unexpected. In fact, it means absence of the positive clinical response despite the fact 
that the immune reaction to the tumor is taken to be enhanced by the vaccine even better 
as compared with the first group. Indeed, we have intentionally taken the bigger relative 
growth of parameters e, g, and j for P2 in comparison with P1.  
Figure 7 shows the results of the vaccination after surgery and Figure 8 shows the 
case without preliminary treatment. In the first case, using vaccine without delay allows 
stunting tumor growth and it reaches the therapeutic saturation level in 70 days. 
Besides, with vaccine the saturation level becomes lower than without therapy. It should 
be noted that the vaccine administered with 10-days delay is not effective because no 
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deceleration of the tumor growth is observed (Figure 7(a)). The vaccination is 
ineffective when it is administered without preliminary surgery (Figure 8(a)).  
It should be noted that the positive response to the treatment can also be described 
within our model. In order to show this possibility we consider the third group of 
patients (P3 in Table 2). In the absence of treatment the tumor grows to the dangerous 
size (see Figure 9). As is seen from Table 4, all of the considered therapeutic regimens 
result in tumor regression to the small volume that corresponds to the stable fixed point 
(spiral node) of the system. For sequential regimens the slower decreasing of the tumor 
volume is found as compared to IL-2 alone, IL-2 plus IFN-α and vaccine therapies. 
There is more pronounced regression of the tumor size in the cases of chemo/immune 
sequence and concurrent chemoimmunotherapy in comparison with the immune/chemo 
sequence. At the same time, we would like to mention more than 50% decrease of the 
tumor size that implies the effectiveness of all considered regimens. Thus, our 
simulations show that after cessation of therapy the tumor regresses.  
The interesting results are obtained in the case of the vaccine therapy (see Figure 
9). We consider the situation when under the vaccine therapy the system passes to the 
region III in Fig.1 (see Table 3). In this case, the effect of vaccine therapy does not 
depend on the initial tumor size and the immune system conditions. As a result, the time 
delay is out of importance (without angiogenesis taken into account). As is seen from 
Figure 9(a), the tumor cells population decreases to a small size. While after the 
termination of the vaccine action the tumor regrows, it nevertheless never exceeds the 
size T1 (corresponding to the stable spiral for P3). 
5. Conclusion 
We have studied the effects of different treatment regimens on both the tumor 
growth and the immune response within the simple ODE model that describes tumor-
immune dynamics with chemotherapy and immunotherapy. It is found that the regime 
of full regression of tumor is not admitted in our model. This conclusion is in agreement 
with some current clinical observations where recurrences of tumors are observed [26]. 
The bifurcation diagram for antigen presentation shows three main dynamical regimes. 
The region I reflects a progressive growth when the tumor is able to escape from the 
immune response. The region II describes two regimens of disease depending on both 
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the initial tumor size and the condition of immune system: (i) the regression to small 
tumor when the dynamical equilibrium is established and (ii) a progressive tumor 
growth to the highest possible size. For the region III the decrease of the tumor size is 
found when the equilibrium between the tumor and the immune system is established. 
In order to describe a possibility of different responses to treatment regimens, 
patients were conditionally divided in three generalized groups. Each group is 
characterized by specific tumor antigen expression, the strength of the immune 
response, and the reaction to vaccination. For patients with a weak immune response the 
vaccine therapy is found to be the most effective in comparison with other described 
treatments when used without time delay from a prescribed date of vaccination after 
surgery. This means that using vaccine gives the best results for patients with both small 
size of tumor and an immune system, which is not suppressed by tumor growth and able 
to respond to the vaccine. For the first group, the vaccine therapy is shown to be the 
only possible treatment allowing long tumor remission. Therefore, we note a promising 
effect of the vaccine treatment to improve immune response for this group. This 
qualitatively agrees with clinically observed results (see, e.g., [40,45,46,50]). For the 
second group all considered treatments result in progressive growth. However, the 
vaccine therapy without delay after surgery is expected to be more sparing. We 
observed that for patients with a strong immune response IL-2 alone, IL-2 plus IFN-α 
and the sequential chemoimmunotherapy could be used as a reasonable alternative to 
vaccination. 
Our study shows that along with progressive disease the positive clinical responses 
to the treatment characterizing by a long remission of tumor growth are possible. This 
qualitatively agrees with modern clinical observations. Indeed, clinical trials of 
chemotherapy and sequential regimens for melanoma showed that along with 
progressive diseases the partial responses and even complete responses were possible 
within patient groups [26]. It was also shown in the trials of the vaccine therapy [45] 
that the CTL response to the vaccine by itself did not guarantee the tumor regression. 
For instance, for several patients the T cell response to the vaccine was found to be not 
strong enough to decrease the tumor size and, as a result, the tumor was progressing. At 
the same time, the tumor regression was observed for few patients with immune 
responses to the vaccine. In our model, these observations could be explained by both 
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heterogeneity of the tumor antigen expression and patient-specific characteristics of 
immune response. 
It should be stressed that all these predictions can be valid only for the description 
of early stages of the tumor growth when the processes of angiogenesis, invasion and 
metastasis are not of critical importance. As the next step, we plan to extend our simple 
ODE model to PDE model to include spatial components for distributions of cells and 
drugs. In this context, the presented analysis is of interest since it gives the underlying 
kinetics of more general PDE model. Notice also that toxicity of both chemotherapy and 
immunotherapy requires finding of an optimal treatment protocol. There are known 
some attempts to examine this problem within appropriate ODE models of tumor-
immune dynamics (see e.g. [3,12,13]) and it would be interesting to consider it within 
our model. These studies are now in progress.  
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Table captions 
Table 1. The parameter set for the first group of patients (P1). 
Parameter Units Description Value Source 
a day−1 Tumor growth rate 0.13 Fit to data [21] 
b cell−1day−1 a/b is a tumor carrying capacity 3×10−10 Fit to data [21] 
cCTL cell−1 day−1 Rate of tumor cells inactivation by CTL 4.4×10−9  
d cell day−1 Rate of steady inflow of CTL 7.3×106 Estimated from [17] 
e cell−1 day−1 CTL proliferation rate induced by IL-2 9.9×10−9  
f day−1 CTL death rate 0.33 Estimated from [6] 
g unit day−1 Antigen presentation 1.6×107  
j cell−1 day−1 Rate of consumption of IL-2 by CTL 3.3×10−9  
k cell−1 day−1 Inactivation of IL-2 molecules by prostaglandines 1.8×10
−8
 
 
l cell Half-saturation constant 3×106  
chemo
TM  day
−1
 
Tumor cell killing by chemotherapy 0.9 
chemo
LM  day
−1
 
CTL killing by chemotherapy 0.6 
Taken from [11] 
p day−1 Decay rate of chemotherapy drug 6.4 Estimated from [29] 
q day−1 Decay rate of therapeutic IFN−α 1.7 Estimated from [43] 
T0 = 108 cells L0 = 9×107 cells I20 = 2×107 units I0 = 107 units 
 
Table 2. The parameter sets for the second (P2) and the third (P3) groups of patients. 
Value 
Parameter 
P2 P3 
a 0.13 0.13 
b 3×10−10 3×10−10 
cCTL 3.3×10−9 5.5×10-9 
d 7.3×106 7.3×106 
e 9.6×10−9 1.0×10-8 
f 0.33 0.33 
g 1.4×107 2.4×107 
j 2.9×10−9 3.7×10-9 
k 1.5×10−8 2.1×10-8 
l 3×106 3×106 
chemo
TM  0.9 0.9 
chemo
LM  0.6 0.6 
p 6.4 6.4 
q 1.7 1.7 
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Table 3. The percent increase of the parameters sensitive to the vaccine 
Increase (in %) Parameter P1 P2, P3 
cCTL 20 10 
e 15 20 
g 20 30 
j 30 50 
 
Table 4.  Effects of different treatments for three groups of patients*. 
P1 P2 P3  
t0 ∆T t0 ∆T t0 ∆T t0 ∆T t0 ∆T 
Chemotherapy ↑ 13.4 ↑ 11.4 ↑ 20 ↑ 0.1 ↓ 0.43 
IL-2 alone ↓ 0.34 ↑ 7.5 ↑ 21 ↓ 0.82 ↓ 0.92 
IL-2 plus IFN-α ↓ 0.42 ↑ 3.9 ↑ 10 ↓ 0.95 ↓ 0.93 
Chemo/immune ↑ 9.92 ↑ 9.3 ↑ 23.9 ↓ 0.68 ↓ 0.88 
Immune/chemo ↑ 12.8 ↑ 10.2 ↑ 24.3 ↓ 0.48 ↓ 0.88 
Chemo + immune ↑ 10.9 ↑ 9.5 ↑ 24 ↓ 0.63 ↓ 0.88 
Vaccine therapy 
without 10 day delay 
6 
↓ 0.25 
3 
↑ 8.92 
6 
↑ 18.7 
3 
↓ 0.91 
6 
↓ 0.91 
*The therapies for P1 and P2 are administered after surgery, and for P3 without previous treatment. The arrow ↑ 
means the increase of the tumor size, ↓ — the decrease of the tumor size. The change of tumor size is presented as ∆T 
= (T(t0) − T(0))/T(0). t0 — the time after the start of treatment, weeks For P1 and P2 the initial conditions are T(0) = 
8×106 cells, L(0) = 2.25×107 cells, I(0) = 2.4×107 cells, for P3 — T(0) = 3×107 cells, L(0) = 3.45×107 cells, I(0) = 
1.7×107 cells 
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Figure captions 
 
Figure 1. A bifurcation diagram varying the antigen presentation (h6). For h6 < h6min there is only one 
steady state — improper node (region I). When h6min < h6 < h6max there are two stable steady states — 
improper node and spiral node as well as an unstable (saddle) point (region II). For h6 > h6max only one 
steady state, the spiral node remains (region III). 
 
Figure 2. Human data, group P1. Effects of chemo-, IL-2 and IL-2 plus IFN−α therapies on tumor and 
immune response dynamics. (a) tumor cells, (b) cytotoxic T cells, and (c) IL-2 vs. time. (d) shows drug 
administration pattern: nine doses, strength VC(t) = 1, 1 day per dose on a 5 day cycle, and IFN−α 
administration pattern: four doses, strength VI(t) = 5 MU/day, 4 days per dose on a 10 day cycle. IL-2 is 
administered with four doses of strength 
2I
V (t) = 10 MU/day, 4 days per dose on a 10 day cycle. Initial 
conditions: 8×106 tumor cells, 2.25×107 cytotoxic T lymphocytes, 2.4×107 IL-2 units.  
 
Figure 3. Human data, group P1. Effects of one pulse of chemotherapy followed immediately by one 
pulse of IL-2-therapy, one pulse of IL-2 therapy followed immediately by one pulse of chemotherapy, and 
concurrent chemoimmunotherapy. (a) tumor cells, (b) cytotoxic T cells, and (c) IL-2 vs. time. (d) shows 
drug administration pattern: one pulsed dose of chemotherapy, strength VC(t) =1 per day, 4 days per dose 
for sequential chemo/immunotherapy (dotted line), sequential immuno/chemotherapy (dash-dot line), and 
concurrent chemoimmunotherapy (gray line). IL-2 administration pattern: one pulsed dose of strength 
2I
V (t) = 10 MU/day, 4 days per dose after chemotherapy (chemo/immunotherapy sequence) or before 
chemotherapy (immuno/chemotherapy sequence) and 
2I
V (t) = 7 MU/day for four days simultaneously 
with chemotherapy (concurrent biochemotherapy). Initial conditions: 8×106 tumor cells, 2.25×107 
cytotoxic T lymphocytes, 2.4×107 IL-2 units.  
 
Figure 4. Bifurcation diagrams showing the effect of vaccine therapy on anti-tumor immune response 
dynamics for P1 and P2. 
 
Figure 5. Human data, group P1. Effects of vaccine administered after surgery without delay and with 
delay for 10 days. (a) tumor cells, (b) cytotoxic T cells, and (c) IL-2 vs. time. Initial conditions: 8×106 
tumor cells, 2.25×107 cytotoxic T lymphocytes, 2.4×107 IL-2 units.  
 
Figure 6. Human data, group P1. Effects of vaccine administered without previous treatment and with 
delay for next 10 days. (a) tumor cells, (b) cytotoxic T cells, and (c) IL-2 vs. time. Initial conditions: 
3×107 tumor cells, 1.35×107 cytotoxic T lymphocytes, 1.8×107 IL-2 units.  
 
Figure 7. Human data, group P2. Effects of vaccine administered after surgery without delay and with 
delay for 10 days. (a) tumor cells, (b) cytotoxic T cells, and (c) IL-2 vs. time. Initial conditions: 8×106 
tumor cells, 2.25×107 cytotoxic T lymphocytes, 2.4×107 IL-2 units.  
 
Figure 8. Human data, group P2. Effects of vaccine administered without previous treatment and with 
delay for next 10 days. (a) tumor cells, (b) cytotoxic T cells, and (c) IL-2 vs. time. Initial conditions: 
3×107 tumor cells, 1.35×107 cytotoxic T lymphocytes, 1.8×107 IL-2 units.  
 
Figure 9. Human data, group P3. Effects of vaccine administered without previous treatment. (a) tumor 
cells, (b) cytotoxic T cells, and (c) IL-2 vs. time. Initial conditions: 3×107 tumor cells, 3.45×107 cytotoxic 
T lymphocytes, 1.7×107 IL-2 units.  
 
 
 26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
 27 
 
a 
 
b 
 
c 
 
d 
 
 
10 20 30 40 50
Time, days
0.5
1
1.5
2
2.5
3
3.5
4
I
F
N
-
Α
M
U
 
Figure 2 
 28 
a 
 
b 
 
c 
 
d 
 
Figure 3 
 29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 
 30 
 
a 
 
b 
 
c 
 
 
 
Figure 5 
 31 
 
a 
 
b 
 
c 
 
 
 
Figure 6 
 32 
 
a 
 
b 
 
c 
 
 
 
Figure 7 
 33 
 
a 
 
b 
 
c 
 
 
 
Figure 8 
 34 
a 
 
b 
 
c 
 
 
Figure 9 
 
 
